Fernando De la Garza-Salazar

14PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Electrical energy generation (incl. renewables, excl. photovoltaics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular medicineComputational imaging
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Nov 29, 2025
From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies.

Fernando De la Garza Salazar

|Nov 24, 2024
Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study.

Perla R Colunga-Pedraza, Fernando De la Garza-Salazar, Héctor A Vaquera-Alfaro

|Nov 10, 2022
Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof-of-concept case study.

Fernando De la Garza-Salazar, Perla Rocío Colunga-Pedraza, David Gómez-Almaguer

|Apr 26, 2022
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature.

Perla R Colunga-Pedraza, Samantha P Peña-Lozano, Ernesto Sánchez-Rendón

|Nov 30, 2021
Optimizing ECG to detect echocardiographic left ventricular hypertrophy with computer-based ECG data and machine learning.

Fernando De la Garza Salazar, Maria Elena Romero Ibarguengoitia, José Ramón Azpiri López

Pageof 3